Tag: NASDAQ

El Pollo Loco Celebrates National Chicken Month with Special Offers

COSTA MESA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Calling all chicken enthusiasts! El Pollo Loco (Nasdaq:LOCO), the nation’s leading fire-grilled chicken chain, is celebrating National Chicken Month with exciting promotions for guests now through September 30. In honor of the most delicious month of the year, El Pollo Loco is offering special deals that are sure to delight chicken fans. Throughout the month of September, guests who spend $10 will receive a coupon for a $5 2-piece leg and thigh combo meal on their next visit. The Company is also offering $1 off coupons to fans who show their

DNB Financial Corporation Receives All Required Approvals to Acquire East River Bank

DOWNINGTOWN, Pa., Sept. 14, 2016 (GLOBE NEWSWIRE) — DNB Financial Corporation (“DNB”) (NASDAQ:DNBF), the parent company of DNB First, National Association, today announced that it has obtained all required approvals necessary for DNB to consummate its acquisition of East River Bank, Philadelphia, Pennsylvania (“East River”). Approvals included DNB and East River shareholder approvals, and regulatory approval from the Office of the Comptroller of the Currency, the Board of Governors of the Federal Reserve System and the Pennsylvania Department of Banking. When the combination of the two organizations is completed, DNB will have approximately $1.1 billion in assets, $764 million in

Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series

SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) — Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.            About Retrophin Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s

Student Transportation Inc. Reports Fourth Quarter & Fiscal Year 2016 Results

BARRIE, Ontario, Sept. 14, 2016 (GLOBE NEWSWIRE) — Student Transportation Inc. (TSX:STB) (NASDAQ:STB) (“STI” or “the Company”) today announced financial results for the fourth quarter and fiscal year ended June 30, 2016. All financial results are reported in U.S. dollars except as otherwise noted. “We were very pleased with our strong performance and solid results in fiscal 2016 which were in line with our internal objectives and we are well-positioned for continued improvements in fiscal 2017,” said Denis J. Gallagher, STI Chairman and CEO. “Our year-end results reflect the positive impact of our fuel management and early stage returns from strategic

Globe Newswire

Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results

ATLANTA, Sept. 14, 2016 (GLOBE NEWSWIRE) — Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the fourth quarter and 2016 fiscal year ended June 30, 2016, and also provided an update on recent corporate and clinical developments. “Over the last twelve months we have made significant advances with our three next generation direct-acting antivirals that address serious infections with limited therapeutic options. Enrollment is 90% complete in the SPIRITUS Phase 2b trial of vapendavir for the treatment of human rhinovirus infections in moderate and severe asthmatic patients, and we look forward to announcing top-line data from the trial

Proteostasis Therapeutics Announces Closing of Follow-On Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) — Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced the closing of its follow-on public offering of 5,000,000 shares of its common stock at a public offering price of $13.00 per share, before the underwriting discount. All of the shares sold were offered by Proteostasis Therapeutics, Inc. The gross proceeds from the offering are $65 million, before deducting the underwriting discount and expenses associated with the offering payable by the company. In addition, the company has granted

Global Blood Therapeutics Announces Publication of Preclinical Results Supporting GBT440 Program for Hypoxemic Pulmonary Disorders

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced publication of preclinical data supporting the development of GBT440 for the treatment of hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF), in Physiological Reports. To date, GBT has established preclinical proof of concept for GBT1118, a hemoglobin modifier and analog of GBT440, in three different animal models of hypoxia. Data from these models support the potential beneficial effects of hemoglobin modification as a promising therapeutic strategy

Apigee Announces Fourth Quarter and Fiscal 2016 Results

SAN JOSE, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Apigee® (NASDAQ:APIC), the API company, today announced financial results for its fourth quarter and fiscal year ended July 31, 2016. Fiscal Year 2016 For FY 16, Apigee reported total revenue of $92.0 million, up 34% compared to $68.6 million in FY 15.  Apigee reported FY 16 product revenue (defined as license revenue plus subscription and support revenue) of $75.3 million, up 46% compared to $51.6 million in FY 15. Apigee reported FY 16 GAAP gross margin of 70.1%, up from 63.6% in FY 15, and non-GAAP gross margin of 71.8% compared to

Immune Design Announces Proposed Public Offering of Common Stock

SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Immune Design Corp. (Nasdaq:IMDZ) announced today that it plans to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Immune Design. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the

Builders FirstSource, Inc. Announces Modified Dutch Auction Tender Offer for 10.75% Senior Notes Due 2023

DALLAS, Sept. 14, 2016 (GLOBE NEWSWIRE) — Builders FirstSource, Inc. (the “Company”) (Nasdaq:BLDR), a leading supplier and manufacturer of structural and related building products for residential new construction and home repair and remodeling in the United States, today announced the commencement of a cash tender offer to purchase (the “Tender Offer”) up to $50,000,000 aggregate principal amount of its 10.75% Senior Notes due 2023 (CUSIP Nos. 12008R AH0 (144A) and U08985 AD2 (Reg S)) (the “Notes”) at a purchase price per $1,000 principal amount determined in accordance with a modified Dutch auction procedure on the terms and subject to the

Frequency Electronics, Inc. Announces First Quarter Fiscal Year 2017 Results

MITCHEL FIELD, N.Y., Sept. 14, 2016 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (NASDAQ:FEIM) reported revenues for the first quarter of fiscal 2017, which ended July 31, 2016, of $12.7 million as compared to $16.7 million in the same quarter of fiscal 2016.  The Company recorded operating loss of $796,000 for the quarter ended July 31, 2016, compared to an operating profit of $941,000 in the first quarter of fiscal 2016.  Net loss for the first quarter of fiscal 2017 was $706,000 or ($0.08) per diluted share compared to net income of $891,000 or $0.10 per diluted share for the first

U.S. Global Investors Reports Financial Results for Fiscal Year 2016

San Antonio, TX, Sept. 14, 2016 (GLOBE NEWSWIRE) — For Immediate Release U.S. Global Investors Reports Financial Results for Fiscal Year 2016 Continuing Dividends and Share Repurchase Program ************************************************************************ SAN ANTONIO-September 14, 2016 –U.S. Global Investors, Inc. (NASDAQ: GROW), a boutique registered investment advisory firm with longstanding experience in global markets and specialized sectors, today reported a net loss of $3.7 million, or $(0.24) per share, on operating revenues of $5.5 million for the fiscal year ended June 30, 2016. For the fiscal year 2015, U.S. Global Investors recorded a net loss of $4.0 million, or $(0.26) per share, on

Nasdaq Hearings Panel Grants Extension of Exception for Continued Listing of United Development Funding IV Shares

GRAPEVINE, Texas, Sept. 14, 2016 (GLOBE NEWSWIRE) — United Development Funding IV (“UDF IV” or the “Trust”) (NASDAQ:UDF) today announced that the Nasdaq Hearings Panel (the “Panel”) has granted an extension of the exception previously granted for continued listing of the Trust’s common shares on The NASDAQ Stock Market (“Nasdaq”).   The Trust’s continued listing is subject to the condition that, on or before October 17, 2016, the Trust become current in its periodic filings with the Securities and Exchange Commission (the “SEC”).  The Trust must also be able to demonstrate that it satisfies all other quantitative and qualitative requirements for

Nasdaq Included in Dow Jones Sustainability Index

NEW YORK, Sept. 14, 2016 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq:NDAQ) today announced it has been selected to join the Dow Jones Sustainability Indices (DJSI). Nasdaq is one of 16 companies added to the Dow Jones Sustainability North America Index in 2016, which is comprised of 146 companies. Nasdaq actively supports its 3,500 listed companies in their sustainability efforts, and strives to create an open dialogue between listed companies, investors, analysts, regulators, and academics on the economic value of sustainability. Nasdaq also works closely with international groups such as the World Federation of Exchanges, The United Nations Sustainable Stock Exchanges Initiative, and

PDC Energy Closes Common Stock and Convertible Senior Notes Offerings

DENVER, Sept. 14, 2016 (GLOBE NEWSWIRE) — PDC Energy, Inc. (“PDC” or the “Company”) (Nasdaq:PDCE) today announced that it has closed its previously announced concurrent underwritten public offerings of (i) 9,085,000 shares of its common stock (the “common stock”), which number of shares includes 1,185,000 shares issued pursuant to the exercise of the underwriters’ overallotment option, and (ii) $200 million aggregate principal amount of its convertible senior notes due 2021 (the “notes”), which aggregate principal amount includes $25 million issued pursuant to the exercise of the underwriters’ overallotment option. The net proceeds from the common stock offering were approximately $558.8

iSectors, LLC to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Sept. 14, 2016 (GLOBE NEWSWIRE) —              What: iSectors, LLC, a manager of a suite of exchange-traded fund (ETF)-based asset allocation models, will visit the Nasdaq MarketSite in Times Square in celebrating the recent debut its flagship iSectors® Post-MPT Growth ETF (Nasdaq:PMPT). The actively-managed ETF aims to optimize investor return and minimize the downside risk. In honor of the occasion, Charles H. Self III, Chief Operating Officer and Chief Investment Officer of iSectors and Portfolio Manager for PMPT, will ring the Opening Bell.  Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast

Educational Development Corporation Announces Record Net Revenue for the Month of August 2016

TULSA, Okla., Sept. 14, 2016 (GLOBE NEWSWIRE) — Educational Development Corporation (“EDC”) (NASDAQ:EDUC) (http://www.edcpub.com) today reported historic record net revenues for the month of August 2016 (unaudited). Randall White, CEO of Educational Development Corporation, announced that the Company achieved record net revenues of $10.0 million for the month of August compared to $5.0 million for August last year.  The Company was led by the direct sales division, Usborne Books & More (“UBAM”), with net revenues of $9.1 million compared to $3.9 million last August. UBAM continues to attract new sales associates, which now total just under 25,000, compared to 8,500

Nordea to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Sept. 14, 2016 (GLOBE NEWSWIRE) — What: Nordea, the largest financial services group in Northern Europe with a market capitalisation of approximately EUR 41.3 billion, total assets of EUR 6,469 billion, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Nils Lundsby, Director of Business Development, will ring the Closing Bell.  Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio When:Thursday, September 15, 2016 – 3:45 p.m. to 4:00 p.m. ET         Nordea Contact:Nils.Lundsby+45 6122 0350Nils.lundsby@nordea.com Nasdaq MarketSite:Emily Pan(646) 441-5120emily.pan@nasdaq.com Feed Information:Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05

Globe Newswire

Envoy Air Now Offers Industry-Leading Pay for Pilots

IRVING, Texas, Sept. 14, 2016 (GLOBE NEWSWIRE) — Envoy Air Inc., a wholly owned subsidiary of American Airlines Group (NASDAQ:AAL), announced today that it will nearly double the starting rate of pay for new hires, to nearly $38 per hour – effectively starting new hire pilots on Step 3 of the Envoy pilot pay scale. This means that Envoy First Officers can earn $58,000 or more in their first year on the job. The carrier will also increase the pay rates for existing First Officers during their first three years with the airline – and expand its existing First Officer

Feature Box

PetLife Pharmaceuticals Continues Execution of its Vitalzul TM Business Plan with start of Proof of Concept studies; Provides Updates

Hancock, MD, Sept. 14, 2016 (GLOBE NEWSWIRE) — Hancock, MD – PetLife Pharmaceuticals, Inc. (OTC QB: PTLFD) (the “Company”), a developer of Vitalzul™, a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announces plans to begin its Proof of Concept study as part of its pre-INAD (Investigational New Animal Drug) program. The study will be undertaken under contract by InnoVision Therapeutics. Proof of Concept studies are an early stage of clinical drug development when a compound has shown potential in animal models and early safety testing. These small-scale studies are designed to detect a signal that